東陽光(600673.SH):東陽光藥擬放棄公司控股股東下屬藥物研發業務板塊的相關研發成果的優先購買權
格隆匯 3 月 19日丨東陽光(600673.SH)公佈,根據公司控股股東關於避免同業競爭的承諾,公司控股子公司東陽光藥擁有公司控股股東及公司實際控制人下屬藥物研發業務板塊的研發成果的優先購買權。近日,公司收到控股股東的通知,其控股子公司廣東東陽光藥為聚焦於抗感染、抗腫瘤、代謝領域的核心產品線項目的研發,計劃以包括但不限於獨佔許可等方式將其具有獨立知識產權的可溶性鳥苷酸環化酶刺激劑、鹽皮質激素受體拮抗劑、法尼醇X受體激動劑、低氧誘導因子-脯氨酰羥化酶抑制劑、5-HT再攝取抑制劑和5-HT1A受體部分激動劑、FLT3高選擇性抑制劑、Axl和Mer雙靶點小分子酪氨酸激酶抑制劑等7個在研項目的研發及商業化權利進行對外授予,許可費用總額預計為10至15億元人民幣,並詢問東陽光藥是否行使優先購買權。考慮到擬許可項目目前均處於臨牀前研究階段至臨牀I期階段內,項目研發週期較長,預計研發投入大,研發風險較高,且擬許可項目與東陽光藥的適應症領域配置、產品管線佈局及未來發展規劃關聯性不大,如收購該項目產品後續還需要投入大量時間和資金建設、完善相關適應症領域的生產車間和商業推廣團隊,整體成本投入大而收益回報不確定,因此東陽光藥擬放棄該項目的優先購買權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.